AstraZeneca invests Rs 166 crore to expand Bengaluru operations
This investment follows AstraZeneca's recent expansion of its Global Innovation and Technology Centre (GITC) in Chennai.
The company's workforce in India will increase to 4,000 employees, highlighting India's growing significance in AstraZeneca's global operations. The enhanced Bangalore facility will house nearly 1,300 staff members and function as a comprehensive centre supporting AstraZeneca's primary operations in clinical research, AI-driven healthcare solutions, global business services, and regulatory compliance.
"Our global hub in Bengaluru is a strategic investment that strengthens our ambition to deliver 20 new medicines by 2030," said Jackie Crockford, VP of global business services at AstraZeneca.
You Can Also Check:
Bengaluru AQI
|
Weather in Bengaluru
|
Bank Holidays in Bengaluru
|
Public Holidays in Bengaluru
The new facility will serve as a dynamic hub advancing AstraZeneca's critical priorities, including advanced clinical research across global therapeutic areas, development of AI-powered healthcare and digital health technologies, centralized data analytics to improve clinical trial efficiency and patient outcomes, and specialized support for global regulatory compliance and pharmacovigilance. Karnataka health minister Dinesh Gundu Rao said, "This aligns with our vision to drive high-value employment and make Bangalore a biotechnology and R&D powerhouse.
"
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
5 hours ago
- Hans India
AstraZeneca Pharma India's net profit slips 4 pc in Q1
Mumbai: AstraZeneca Pharma India Limited on Thursday reported a 4.12 per cent decline in net profit for the first quarter (Q1) of FY26, with earnings falling to Rs 55.8 crore from Rs 58.2 crore in the previous quarter (Q4 FY25). This dip came despite a strong rise in revenue from operations, which grew 9.56 per cent sequentially to Rs 526.3 crore from Rs 480.4 crore, according to its stock exchange filing. Other income saw a sharp decline of 30.43 per cent, dropping to Rs 11.2 crore from Rs 16.1 crore in Q4 FY25. However, total income rose 8.23 per cent to Rs 537.5 crore from Rs 496.6 crore, driven by solid operational performance. Total expenses increased by 12.12 per cent to Rs 462.4 crore, compared to Rs 412.4 crore in the previous quarter, the company stated in its regulatory filing. Bhavana Agrawal, Chief Financial Officer and Director of the Company, said the strong quarterly performance reflects the power of science-led innovation combined with disciplined execution. 'Each regulatory milestone brings us closer to transforming outcomes for patients living with chronic diseases. We remain focused on expanding our portfolio, strengthening partnerships, and ensuring that breakthrough medicines reach the people who need them most,' she added. Praveen Rao Akkinepally, Country President and Managing Director, said that delivering consistent growth across therapy areas reaffirms the strength of the company's 'Growth Through Innovation' strategy. 'These results are a testament to what is possible when science and purpose come together,' he noted. AstraZeneca, a global science-led biopharmaceutical company, focuses on the discovery, development, and commercialisation of prescription medicines, primarily in oncology, cardiovascular, renal and metabolism, respiratory, and rare diseases. The company operates in over 100 countries, with its medicines used by millions of patients worldwide. Completing 45 years in India, AstraZeneca Pharma India Limited is headquartered in Bengaluru and employs over 600 people across the country.
Time of India
21 hours ago
- Time of India
790 snakebite incidents reported in Mys dist in 2024
Mysuru: Compared to 2023, the number of snakebite incidents have more than doubled in most of Mysuru region in 2024. The data presented by health and family welfare department revealed that Mysuru district recorded four deaths due to snakebites in 2024. According to experts, most of these cases are reported from rural areas. According to the data presented by state health and family welfare minister, Dinesh Gundu Rao, to a question raised by MLC S Ravi in the ongoing legislative council session, as many as 790 snakebite cases were reported in Mysuru district in 2024. There were 323 cases in 2023 and 189 in 2022. A snake rescuer and former corporator, Balasubramanyam, popularly known as Snake Shyam, said most of the snakebites related calls and snake rescue are by farmers and farm labourers. "In urban areas, snakebite incidents are rare. But it is the highest in rural areas, especially in farms, paddy, and sugar cane fields," he explained. "Awareness about snakebites can prevent these incidents," he said. According to Bagadalapura Nagendra, president of Karnataka Rajya Raita Sangha and Hasiru Sene, most of the victims are either farmers or farm labourers. "Last year, a lot of snakebite incidents were reported among farmers, especially during farm work, as snakes came out of the anthills following heavy rainfall," he said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Austria: New Container Houses (Prices May Surprise You) Container House Search Now Undo "Snakebite incidents are common among farmers' families. The govt must start providing treatment for snakebites in taluk hospitals," he said. "Currently, farmers are paid Rs 2 lakh compensation in the event of a snakebite death. But many are missing out as submitting the copy of RTC is mandatory to get compensation. This rule must be changed," he said. BOX Dist-wise data of incidents* Districts | 2022 | 2023 | 2024 | Kodagu | 134 (1) | 163 (0) | 331 (1) | C'magaluru | 145 (0) | 291 (0) | 362 (3) | Ch'nagar | 35 (0) | 56 (0) | 261 (1) | Hassan | 171 (0) | 505 (0) | 850 (2) | Mandya | 156 (0) | 302 (4) | 763 (5) | S'mogga | 117 (0) | 274 (0) | 699 (6) | *(deaths in brackets) Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
Time of India
a day ago
- Time of India
AI-based screening detects five cancer cases in early stages
Low dose Chest CT scan for individuals with a significant history of exposure to tobacco between the ages of 55 to 74, has been validated as a screening tool for early diagnosis of lung cancer. Panaji: The AI-driven early detection of lung cancer screening has been carried out across all levels of the public health system for free in Goa since Feb 2024. Over 75,000 chest X-rays have been screened, detecting over 6,000 pulmonary nodules and flagging more than 500 people with high risk for lung cancer. It also detected five lung cancer cases that would have otherwise gone undetected. Under the public-private partnership, Goa, in partnership with AstraZeneca and is the first state in the country to deploy artificial intelligence for lung cancer screening in the public sector. This was presented at the 78th World Health Assembly in Geneva in May by the state nodal officer for non-communicable disease cell, Dr Kedar Raikar. The screening currently takes place at 17 public health centres and hospitals. It is integrated with the existing digital X-ray network and conducts chest X-rays, CT scans, and follow-ups. The programme has reduced the wait time for CT scan from 10 days to 2 days for high-risk patients. The system helps flag potential signs on routine X-rays even when patients come in for completely unrelated issues. Before the system was brought in, 100 to 200 lung cancer cases would be detected over a two-year period. A pink slip is given to high-risk patients to ensure they receive prioritised care quickly. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
